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Background: Cancer-testis (CT) antigen genes might promote the progression of multiple myeloma (MM). CT
antigens may act as diagnostic and prognostic markers in MM, but their expression levels and clinical implications
in this disease are not fully understood. This study measured the expression levels of four CT antigen genes in
Chinese patients with MM and explored their clinical implications.
Methods: Real-time quantitative polymerase chain reaction (qPCR) was used to quantify the expression of
MAGE-C1/CT7, MAGE-A3, MAGE-C2/CT10 and SSX-2 mRNA in 256 bone marrow samples from 144 MM patients.
Results: In the newly diagnosed patients, the positive expression rates were 88.5% for MAGE-C1/CT7, 82.1% for
MAGE-C2/CT10, 76.9% for MAGE-A3 and 25.6% for SSX-2. The expression levels and the number of co-expressed CT
antigens correlated significantly with several clinical indicators, including the percentage of plasma cells infiltrating
the bone marrow, abnormal chromosome karyotypes and the clinical course.
Conclusion: MAGE-C1/CT7, MAGE-A3, MAGE-C2/CT10 and SSX-2 expression levels provide potentially effective
clinical indicators for the auxiliary diagnosis and monitoring of treatment efficacy in MM.
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Multiple myeloma (MM) is the second most common
hematological cancer but the search for useful molecular
markers in patients with MM has been highly challen-
ging. The cancer-testis (CT) antigens are normally
expressed in the testicles and trophoblastic cells of the
ovary, and are also detected in some malignant tumors,
such as MM and gastrointestinal stromal tumors [1-6].
CT antigens are capable of evoking spontaneous humoral
and T-cell mediated immune responses and, due to their
tumor-specific expression pattern and immunogenicity,
CT antigens are considered as diagnostic tumor markers
and potential targets for immunotherapy [7]. In addition,
CT antigens are correlated with prognosis in pharyngeal
cancer and non-small cell lung cancer [8,9].* Correspondence: xjhrm@medmail.com.cn; ruanguorui@pkuph.edu.cn
Peking University People’s Hospital and Institute of Hematology, Beijing Key
Laboratory of Hematopoietic Stem Cell Transplantation, No.11 Xi-Zhi-Men
South Street, 100044 Beijing, China
© 2014 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.Although recent studies have shown that CT antigens
are widely expressed at the mRNA and protein levels in
MM patients [2], and are correlated with clinical out-
comes and shorter survival durations [1,10-12], the
patterns of expression and clinical implications of CT
antigens have not been fully characterized. Additional
data on the expression levels of CT antigens in MM may
provide useful information to complement recent devel-
opments in diagnostic criteria and prognostic factors,
and accelerate the development of effective individual-
ized clinical treatment strategies for MM patients.
This study aimed to measure the expression levels of
four CT antigen genes, MAGE-C1/CT7, MAGE-A3,
MAGE-C2/CT10 and SSX-2, in samples of bone marrow
from Chinese patients with MM using real-time quanti-
tative PCR (qPCR), and to explore the clinical implica-
tions of CT antigen gene expression levels. The results
of this study strongly suggested that MAGE-C1/CT7,
MAGE-A3 and MAGE-C2/CT10 expression levels couldLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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monitoring of treatment efficacy in MM.Results
The expression frequency of the four CT antigen genes in
multiple myeloma
In the newly diagnosed patients, 92.3% (72/78) of speci-
mens expressed at least one of the four CT antigen
genes. The rank of the positive expression rate in the
newly diagnosed MM patients was MAGE-C1/CT7
(88.5%, 69/78) >MAGE-C2/CT10 (82.1%, 64/78) >MAGE-
A3 (76.9%, 60/78) > SSX-2 (25.6%, 20/78). When the sam-
ples of patients who responded to treatment (complete
response, CR or partial response, PR) were included, the
percentage that expressed MAGE-C1/CT7, MAGE-A3,
MAGE-C2/CT10 or SSX-2 was reduced to 67.3% (76/113),
45.1% (51/113), 46.0% (52/113) and 10.6% (12/113), re-
spectively (p < 0.05 for all). In non-responding patients, the
rates of positive expression of the four genes increased
significantly to 81.1% (43/53), 79.2% (42/53), 81.1% (43/53)
and 32.1% (17/53), respectively (Table 1). All samples
derived from the 22 healthy stem cell transplantation
donors were negative for all four CT antigens.
The expression frequency of all four CT antigen genes
was significantly higher in patients with BM plasma cell
infiltration (≥10% vs. <10%). Additionally, MAGE-A3
was expressed at a higher rate in patients with a β2-
microglobulin level ≥3.5 mg/L compared to <3.5 mg/L
(80.7% vs. 59.5%, p = 0.01). MAGE-A3 was also increased
with ISS staging (I: 57.1% vs. II: 66.7% vs. III: 85.2%, p = 0.02)
(Table 2). No significant association could be found
between the expression frequency of all four CT antigen




Newly diagnosed patients (n = 78) 69 (88.5%) 60 (76.9%)
In remission (n = 113) 76 (67.3%) 51 (45.1%)
Non-responders (n = 53) 43 (81.1%) 42 (79.2%)
Relapsed patients (n = 12) 10 (83.3%) 9 (75.0%)
*p-value <0.01 <0.01
Percentage of patie
0 gene 1 gene
Newly diagnosed patients (n = 78) 6 (7.7%) 4 (5.1%)
In remission (n = 113) 23 (20.4%) 32 (28.3%)
Non-responders (n = 53) 1 (2.1%) 9 (16.7%)
Relapsed patients (n = 12) 0 (.0%) 0 (0%)
*p-value <0.01 0.01
*p-values compared with newly diagnosed patients, patients in remission and thoseCo-expression patterns of CT antigen genes in multiple
myeloma
The co-expressed numbers of CT antigen genes of pa-
tients in remission decreased compared to those of un-
treated patients, non-responders to treatment, or relapsed
patients (Table 1), which indicated that the co-expression
of CT antigens was related to disease status.
We then analyzed the relationship between CT antigen
expression and the clinical indices of MM. There was a
moderate positive correlation between the co-expression
of CT antigens and the percentage of BM plasma cell
infiltration (r = 0.51, n = 244, p < 0.01). The co-expression
of CT antigens was marginally correlated with the per-
centage of del(13q14) positive cells (r = 0.44, n = 30,
p = 0.01), the percentage of del(13q14.3) positive cells
(r = 0.42, n = 26, p = 0.02), β2-microglobulin levels (r = 0.27,
n = 178, p < 0.01), paraprotein levels (r = 0.16, n = 164,
p < 0.05), urinary free light chain levels (r = 0.21, n = 126,
p = 0.02), serum calcium levels (r = 0.19, n = 199, p < 0.01),
and blood sedimentation rates (ESR; r = 0.30, n = 145,
p < 0.01). CT antigens were negatively correlated with
hemoglobin levels (Hb: r = −0.24, n = 205, p < 0.01).
CT antigen expression levels correlate with the
percentage of plasma cells in bone marrow samples
The levels of CT antigen expression were detected by
qPCR assays. The results showed that the percentages of
BM plasma cell infiltration in 244 samples were posi-
tively correlated with expression levels of MAGE-C1/
CT7 (r = 0.50), MAGE-A3 (r = 0.51), MAGE-C2/CT10
(r = 0.56) and SSX-2 (r = 0.23), respectively (all p < 0.01).
Additionally, flow cytometry was used in 150 patients to
detect the proportion of abnormal plasma cells. The
expression levels of MAGE-C1/CT7 (r = 0.43), MAGE-nd co-expression of the four CT antigens in patients with
ntage of patients with positive expression
MAGE-C2/CT10 SSX-2 ≥1 CT antigen gene
64 (82.1%) 20 (25.6%) 72 (92.3%)
52 (46.0%) 12 (10.6%) 90 (79.6%)
43 (81.1%) 17 (32.1%) 52 (98.1%)
9 (75.0%) 7 (58.3%) 10 (83.3%)
<0.01 <0.01 <0.01
nts with positive co-expression of the four CT antigens
2 genes 3 genes 4 genes
14 (17.9%) 35 (44.9%) 19 (24.4%)
22(19.5%) 27 (23.9%) 9 (8.0%)
6 (10.4%) 23 (43.8%) 14 (27.1%)
2 (20.0%) 3 (20.0%) 7 (60.0%)
0.42 <0.01 <0.01
that were non-responders to treatment using the chi-square test.
Table 2 Correlation of the clinicopathological characteristics of patients with MM with the expression of CT antigens
Characteristics n MAGE-C1 (%) MAGE-A3 (%) MAGE-C2 (%) SSX (%)
Age (years) p = 0.36 p = 0.07 p = 0.35 p = 0.19
<60 84 81.0 64.3 71.4 29.8
≥60 60 86.7 78.3 78.3 20.0
Sex p = 0.94 p = 0.09 p = 0.57 p = 0.06
Male 95 83.2 74.7 75.8 30.5
Female 49 83.7 61.2 71.4 16.3
ISS staging p = 0.19 p = 0.02* p = 0.97 p = 0.12
I 21 85.7 57.1 81.0 14.3
II 42 95.2 66.7 78.6 23.8
III 61 83.6 85.2 78.7 36.1
Unknown 20
BM-infiltrating plasma cells p < 0.01* p < 0.01* p < 0.01* p = 0.03*
<10% 64 73.4 50.0 54.7 17.2
≥10% 78 91.0 87.2 91.0 33.3
Unknown 2
β2-microglobulin (mg/L) p = 0.19 p = 0.01* p = 0.12 p = 0.52
<3.5 37 75.7 59.5 67.6 24.3
≥3.5 83 85.5 80.7 80.7 30.1
Unknown 24
*A significant association as analyzed by the chi-square test.
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(r = 0.25) were all significantly correlated with the per-
centages of abnormal plasma cells (p < 0.01 for all).
CT antigen expression levels correlate with prognostic
indices of multiple myeloma
Levels of β2-microglobulin, the most important and reli-
able prognostic factor in MM, were correlated with
MAGE-C1/CT7 (r = 0.21), MAGE-A3 (r = 0.30), MAGE-
C2/CT10 (r = 0.25) and SSX-2 (r = 0.20) in 178 samples
(all p < 0.01).
Multivariate Cox regression analysis was performed in
107 patients who had overall survival (OS) data to com-
pare the prognostic values of β2-microglobulin and the
expression levels of the four genes. β2-microglobulin
(p = 0.03), MAGE-C1/CT7 (p = 0.04) could indicate poor
OS rates with a significant prognostic value.
Furthermore, the expression levels of all four genes
were also correlated with Hb levels (r = −0.17 ~ −0.31,
n = 205, p < 0.01) and ESR (r = −0.23 ~ −0.31, n = 148,
p < 0.01). Furthermore, ages was correlated with MAGE-
C1/CT7 (r = 0.24), MAGE-A3 (r = 0.29) and MAGE-C2/
CT10 expression (r = 0.25) in all patients (p < 0.01 for all).
FISH analyses [including 1q21, del(13q14), del(13q14.3),
14q32 and del(17p13)] were performed in some MM
patients. These have been traditionally regarded as
good prognostic markers of poorer outcome [13]. In
our present study, MAGE-C1/CT7 was observed to bepresent more frequently in patients with del(13q14)
(p = 0.03). Additionally, there were higher expression
levels of MAGE-C1/CT7 (p < 0.01), MAGE-A3 (p = 0.03)
and MAGE-C2/CT10 (p = 0.01) in patients with del
(13q14), higher levels of MAGE-C2/CT10 in patients with
1q21 (p = 0.02) and MAGE-C1/CT7 in patients with del
(13q14.3) (p = 0.04). However, there were no significant
differences in the expression levels of the four CT antigen
genes in patients either with or without the other cytogen-
etic abnormalities. The expression of MAGE-C1/CT7,
MAGE-A3 and MAGE-C2/CT10 in patients with 1q21,
del(13q14) and del(13q14.3) exhibited an increasing trend.
Nevertheless, the expression of MAGE-C1/CT7, MAGE-
A3 and MAGE-C2/CT10 showed a decreasing trend in
six patients with del(17p13) (Table 3), which requires
further analysis. In addition, the expression levels of the
four genes were significantly correlated with the percent-
age of del(13q14)-positive cells (MAGE-C1/CT7: r = 0.37,
p = 0.03; MAGE-A3: r = 0.34, p < 0.05; MAGE-C2/CT10:
r = 0.59, p < 0.01; and SSX-2: r = 0.38, p = 0.03). The above
findings indicated an association between cytogenetic
abnormalities and three CT antigen genes.
CT antigen expression levels correlate with the clinical
course of multiple myeloma
A longitudinal analysis was performed on 58 MM
patients during follow-up (median of three samples per
patient; range: 2–9 samples). In order to facilitate the
Table 3 Correlation of cytogenetic characteristics with CT antigen expression
Characteristics n MAGE-C1 MAGE-A3 MAGE-C2 SSX
Level (Positive percentage) Level (Positive percentage) Level (Positive percentage) Level (Positive percentage)
Del(13q14) p < 0.01* (0.03*) p = 0.03* (0.10) p = 0.01* (0.20) p = 0.25(0.15)
No 44 214.94 ± 830.59(72.7) 8.26 ± 27.53(65.9) 2.50 ± 8.54(70.5) 0.06 ± 0.22(15.9)
Yes 30 443.20 ± 838.11(93.3) 36.85 ± 127.23(83.3) 23.77 ± 98.61(83.3) 0.02 ± 0.06(30.0)
1q21 p = 0.13(0.68) p = 0.11(0.10) p = 0.02* (0.87) p = 0.19(0.15)
No 44 207.45 ± 644.43(79.5) 6.89 ± 24.76(65.9) 0.60 ± 1.41(75.0) 0.04 ± 0.19(15.9)
Yes 30 454.18 ± 1050.80(83.3) 38.86 ± 127.58(83.3) 26.56 ± 98.45(76.7) 0.04 ± 0.14(30.0)
Del(17p13) p = 0.85(0.59) p = 0.69(1.00) p = 0.38(1.00) p = 0.19(0.33)
No 68 327.33 ± 868.73(79.4) 21.57 ± 87.60(72.1) 12.08 ± 66.07(75.0) 0.05 ± 0.18(23.5)
Yes 6 82.53 ± 118.21(100.0) 0.31 ± 0.53(83.3) 0.32 ± 0.74(83.3) 0.00 ± 0.00(0)
14q32 p = 0.79(0.94) p = 0.67(0.05) p = 0.68(0.42) p = 0.74(0.86)
No 31 251.88 ± 645.46(80.60) 34.07 ± 125.46(61.30) 20.45 ± 95.93(71.00) 0.08 ± 0.26(22.60)
Yes 43 347.56 ± 954.95(81.40) 9.60 ± 28.30(81.40) 4.40 ± 17.23(79.10) 0.02 ± 0.07(20.90)
Del(13q14.3) p = 0.04* (0.07) p = 0.18(0.27) p = 0.21(0.45) p = 0.22(0.16)
No 48 233.06 ± 815.48(75.00) 7.71 ± 26.40(68.80) 2.62 ± 8.19(72.90) 0.05 ± 0.21(16.70)
Yes 26 444.86 ± 870.69(92.30) 42.25 ± 136.20(80.80) 26.83 ± 105.86(80.80) 0.02 ± 0.06(30.80)
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course of each patient were divided into three groups:
improved (31 paired samples), stabilized (64 paired sam-
ples) and progressing disease (17 paired samples). The
paired samples comprised samples before and after the
change. Rank correlation analysis showed that the dif-
ferences in the expression levels of MAGE-C1/CT7,
MAGE-A3 and MAGE-C2/CT10 before and after the
changes were consistent with the clinical course of in-
dividual patients (MAGE-C1/CT7: r = 0.36; MAGE-A3:
r = 0.38; MAGE-C2/CT10: r = 0.28; all p < 0.01).
Patients who failed to respond to chemotherapy showed
consistently high expression levels of MAGE-C1/CT7,
MAGE-A3 and MAGE-C2/CT10. The increased expres-
sion levels of the CT antigens exhibited a relapse or a
progressive disease, and were correlated closely with
clinical variables.
In contrast, patients who successfully responded to
chemotherapy showed significant reductions in the expres-
sion levels of MAGE-C1/CT7, MAGE-A3 and MAGE-C2/
CT10. Additionally, their numbers of BM infiltrating
plasma cells, paraprotein and β2-microglobulin levels
were also decreased. Patients who received auto-HSCT
displayed a negative expression or reduced expression
levels of MAGE-C1/CT7, MAGE-A3 and MAGE-C2/
CT10, which indicated a persistent and deeper level of
remission. However, one patient who relapsed after
auto-HSCT showed an increased expression level of
MAGE-A3, and the other two patients who relapsed
after auto-HSCT exhibited increased expression levels
of all three genes (Figure 1).Discussion
This study is the first quantitative analysis of the expres-
sion levels of four CT antigen genes, MAGE-C1/CT7,
MAGE-A3, MAGE-C2/CT10 and SSX-2, in bone mar-
row cells from MM patients using qPCR to investigate
the correlation between CT antigen expression levels and
various clinical characteristics in MM. These results indi-
cate that CT antigens are potentially effective molecular
markers of MM, and have clinical implications for the
auxiliary diagnosis and monitoring of treatment efficacy.
Our qPCR protocol provided a reliable and sensitive
method for the quantification of MAGE-C1/CT7,
MAGE-A3, MAGE-C2/CT10 and SSX-2 expression
levels. The detection sensitivity was approximately 1–10
copies for plasmid DNA standards and 10-4 - 10-5 in
bone marrow specimens which gave a high level of sen-
sitivity and was less time-consuming than traditional
RT-PCR [1] or immunohistochemical methods [14].
The four CT antigen genes were expressed at a high
frequency in MM patients. MAGE-C1/CT7 was the
most commonly expressed gene in newly diagnosed and
relapsed patients, followed by the expression levels of
MAGE-A3, MAGE-C2/CT10 and SSX-2. The positive
expression rate of the four CT antigens was significantly
lower in patients who responded to treatment, and the
CT antigens were not detected in the bone marrow spec-
imens of normal volunteers. These findings indicated
that MAGE-C1/CT7, MAGE-A3, MAGE-C2/CT10 and
SSX-2 were prominent MM-related tumor-specific






















































































































































Figure 1 CT antigen expression levels correlate with the clinical course of multiple myeloma. The expression levels of MAGE-C1/CT7
(A), MAGE-A3 (B) and MAGE-C2/CT10 (C) increased in eight patients who did not respond to treatment and showed non-remission courses with
time. (D, E, F) The expression levels of the three CT antigen genes were reduced in 11 patients who responded to treatment. (G, H, I) Four
patients with de novo disease experienced partial remission and then disease progression; the expression levels of the three CT antigen genes fell
and then rose in two patients, while the other two patients showed increased expression levels before the disease progressed at later time points.
(J, K, L) The expression levels of the three CT antigen genes were reduced or negative in 13 patients after auto-HSCT. In three patients who
relapsed after auto-HSCT, one had an increased expression level of MAGE-A3, and the other two had increased expression levels of all three genes.
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both the number of co-expressed CT antigens and the
expression levels of MAGE-C1/CT7, MAGE-A3, MAGE-
C2/CT10 and SSX-2 were associated with the percentage
of plasma cells that infiltrated the bone marrow. This find-
ing suggested that patients expressing multiple and/or
high levels of CT antigens had a higher load of myeloma
cells. Previous results had demonstrated that the MAGE-
C1/CT7 and MAGE-A3 were expressed in isolated plasma
cells using anti-CD138–conjugated magnetic beads [15],
and the expression levels of both genes were associated
with the numbers of CD138-positive plasma cells.
In addition, the patterns of change observed in the
expression of CT antigens were consistent with the clin-
ical course of MM. Increasing CT antigen expression
indicated relapsing or progressive disease, and reduced
levels or negative CT antigen expression levels occurred
during treatment response. Therefore, the CT antigen
expression levels could reflect the clinical status of MM,
and may have clinical value for the monitoring of disease
progression and evaluating of treatment efficacy.
Finally, the prognostic ability of the four CT antigens
in MM was analyzed. The expression levels of MAGE-
C1/CT7, MAGE-A3, MAGE-C2/CT10 and SSX-2 werecorrelated with prognostic factors for MM, including β2-
microglobulin, abnormal chromosome karyotypes, age
and the hemoglobin level. It appeared that MAGE-C1/
CT7 had a similar prognostic value to β2-microglobulin,
which is currently the most valued prognostic indictor
for MM. Accordingly, MAGE-C1/CT7 was identified as
the leading candidate as a prognostic indictor compared
to the other three genes. Chromosomal abnormalities,
including 1q21, del(13q14) and del(13q14.3), were asso-
ciated with poor survival rates and a more aggressive
disease course [13]. In the present study, higher expres-
sion levels of MAGE-C1/CT7, MAGE-A3, MAGE-C2/
CT10 were found in patients with del(13q14), higher
levels of MAGE-C2/CT10 were found in patients with
1q21 and MAGE-C1/CT7 was more commonly found in
patients with del(13q14.3), which indicated that the three
genes had the same negative effect on prognosis. Del
(17p13) was also found to be an important molecular
cytogenetic marker for poor prognosis. The expression
of MAGE-C1/CT7 has been reported to be more
frequent in patients with del(17p13) (p = 0.047) [16].
MAGE-C1/CT7, MAGE-A3 and MAGE-C2/CT10 showed
a decreasing trend in six patients with del(17p13), but the
correlation between CT antigen gene expression and del
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of patients.
The correlations between MAGE-C1/CT7, MAGE-A3,
MAGE-C2/CT10 or SSX-2 expression and clinical indi-
cators in the present study suggest that each CT antigen
has a unique role in MM. The expression of MAGE-C1/
CT7 was the most useful indictor in patients with MM,
while MAGE-A3 and MAGE-C2/CT10 might confer an
additive value for the prediction of disease complications
and prognosis. A previous study showed that MAGE-A3
was also expressed in patients with MGUS and mye-
loma, which suggested that the expression of MAGE-A
family members could be a common phenomenon or
perhaps even an early event in the evolution of plasma-
cell diseases [15]. SSX-2 was expressed at very low levels
in MM patients. Nevertheless, the positive expression of
SSX-2 in patients with MM may still have a value for the
diagnosis and prognosis of MM patients. It had been
reported previously that SSX-2 levels were significantly
associated with an adverse prognosis and reduced sur-
vival [17], and future studies will define the role of
SSX-2 expression in MM pathogenesis.
Conclusion
MAGE-C1/CT7, MAGE-A3, MAGE-C2/CT10 and SSX-2
were found to be frequently expressed in MM patients.
The positive expression of CT antigens, their co-expressed
numbers, and the expression levels were significantly asso-
ciated with recognized clinical indicators that reflect the
severity of the disease, including BM plasma cells, β2-
microglobulin and abnormal chromosome karyotypes.
The expression levels of MAGE-C1/CT7, MAGE-A3 and
MAGE-C2/CT10 were also correlated with clinical course.
The expression levels of the four CT genes could be
potentially used as clinical indicators for the auxiliary
diagnosis and monitoring of treatment efficacy in MM
patients. To improve the diagnosis and treatment of MM
patients, the roles of CT antigens in the development and
progression of this disease await clarification.
Methods
Patients
Between November 2006 and December 2010, 144 MM
patients were enrolled in this study; 78 (54.2%) patients
were newly diagnosed, 17 (11.8%) had a complete re-
sponse (CR), 24 (16.7%) had a partial response (PR), five
(3.5%) had a progressive disease (PD), 10 (6.94%) had
stable disease (SD) and 10 (6.94%) were from patients
with relapsed disease. The median patient age was 58
years, and 66.0% of patients were male. The clinical data
of all patients is showed in Table 1.
The most common isotype was IgGκ 44 (30.6%), 29
(20.1%) were IgGλ, 14 (9.7%) were IgAκ, 18 (12.5%) were
IgAλ, 6 (4.2%) were IgDλ, 18 (12.5%) were κ light chainisotype, 11 (7.6%) were λ light chain isotype and four
(2.8%) patients had nonsecretory MM. Most patients
after diagnosis accepted four cycles of induction treat-
ments that included BD (consisting of intravenous borte-
zomib at 1.0 or 1.3 mg/m2 on days 1, 4, 8, and 11, 40 mg
dexamethasone on days 1 to 4, followed by a 3-week rest
period) or TD (thalidomide given orally at 200 mg/d; and
dexamethasone given orally at 40 mg on days 1 to 4,
followed by a 4-week rest period). The therapeutic re-
sponse was assessed after induction treatments. If PR
occurred, patients proceeded to autologous hematopoietic
stem cell transplantation (auto-HSCT). Both transplanted
and non-transplanted patients received maintenance ther-
apy with thalidomide (75–200 mg/d) plus dexamethasone
(20–40 mg/d) for 1 year. Diagnosis, staging and thera-
peutic effects were defined using widely used standard
criteria [18,19]. Informed consent was obtained from all
patients and 22 allogeneic stem cell transplantation do-
nors prior to their enrollment in the study. The study
design adhered to the principles of the Helsinki Declaration
and was approved by the ethics committee of Peking
University People’s Hospital.
Bone marrow samples and sample preparation
Two-hundred and fifty-six BM samples were obtained
from patients with MM during routine diagnostic pro-
cedures at the Peking University People’s Hospital.
Mononuclear cells were isolated from BM samples using
standard Ficoll-Hypaque density gradient centrifugation.
RNA was extracted from mononuclear cells using the
TRIzol technique (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. cDNA was synthe-
sized as previously described [20].
Real-time quantitative PCR
The primers and probes were designed using Primer
Express 2.0 software (Applied Biosystems, Foster City,
California, USA) as follows: ABL (forward 5′-CCGCTGAC
CATCAATAAGGAA-3′, reverse 5′-GATGTAGTTGCTT





3′), MAGE-A3 (forward 5′-GGTGAGGAGGCAAGGT
TCTGA-3′, reverse, 5′-GTGCTGACTCCTCTGCTCA
AGAG-3′ and probe, 5′-FAM-AGATCTGCCAGTGG
GTCTCCATTGCC-BHQ-3′), MAGE-C2/CT10 (forward
5′-GTGTGAGGCACACAGCCTAAAG-3′, reverse 5′-GG
AGGCATGACGACTTCTTCA-3′ and probe 5′-FAM-
AGGAGTCAAGGCCTGTTGGATCTCATCA-BHQ-3′)
and SSX-2 (forward 5′-TAACCGTGGGAATCAGGTT
GA-3′, reverse 5′-CCTCCGAATCATTTCCTTCCT-3′
and probe 5′-FAM-CCGAAGATCATGCCCAAGAAGCC
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5 μl 1× TaqMan® Universal PCR Master Mix (Applied
Biosystems, Foster City, California, USA), 400 nM primers,
250 nM fluorescent probes and 150–500 ng cDNA. PCR
was performed using the ABI PRISM® 7500 FAST Sequence
Detection System (Applied Biosystems) at 50°C for 2 min
and 95°C for 10 min, followed by 50 cycles at 95°C for
15 s and 60°C for 1 min. The expression levels of the
four CT antigen genes (MAGE-C1/CT7, MAGE-C2/
CT10, MAGE-A3 and SSX-2) were quantified by qPCR
using the abelson (ABL), glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), beta-glucuronidase (GUS) and
β2-microglobulin (β2M) genes as internal control genes,
respectively, as described previously [21,22]. On the basis
of our previous study of the four control genes, ABL was
a more appropriate control gene in MM patients (Clinical
and Experimental Medicine, accepted, DOI:10.1007/
s10238-013-0257-2, 2013). Therefore, the copy numbers
of the four CT antigen genes and ABL were calculated
using the Ct values on standard curves, and results were
analyzed following the guidelines proposed by the Euro-
pean Study Group for qPCR [23].
Serial dilutions of the plasmids (106, 105, 104, 103, 102,
101 and 10° copies) that expressed ABL and the four CT
antigen genes were amplified by qPCR to construct stand-
ard curves for quantification, respectively. The plasmids
were prepared as previously described 18. A linear correl-
ation was observed between the Ct values and plasmid
copy number, with a correlation coefficient of >0.99 for all
curves. The standard curves revealed a similar efficiency
of amplification for ABL, MAGE-C1/CT7, MAGE-A3,
MAGE-C2/CT10 and SSX-2, with slopes of −3.22, −3.28,
−3.57, −3.43 and −3.51, respectively. As the amplification
efficiency was similar for all genes, the CT antigens were
quantified against the ABL standard curve in bone mar-
row specimens to decrease experimental error. For each
measurement, the curve threshold amplification was set at
0.08 for ABL and the other three CT antigen genes. The
detection sensitivity was approximately 1–10 copies in the
plasmid DNA standards and 10-4 - 10-5 in CT antigen-
positive bone marrow specimens.Flow cytometry
Fresh BM samples were analyzed using standard flow
cytometry using a four-color immunofluorescence tech-
nique as previously described [24]. BM samples were an-
alyzed for the surface and cytoplasmic staining of CD19,
CD38, CD45, CD56, CD117, CD138, κ and λ, amongst
others, to identify malignant plasma cells.Cytogenetics
Cytogenetic FISH analyses were performed using stand-
ard methods [25]. The definition of a cytogenetic cloneand the karyotype descriptions followed the International
System for Human Cytogenetic Nomenclature.
Statistical analysis
All statistical analyses were performed using SPSS 13.0
(SPSS Inc., Chicago, IL, USA). Analysis of variance was
used for continuous variables and χ2 tests were used for
categorical variables. The correlation between the clinical
indices and the expression level of the four CT antigen
genes were analyzed using linear correlation analysis.
Multivariate Cox regression analysis was performed to
compare the prognostic value. Rank correlation analyses
were used to assess the correlation between the clinical
course and the expression levels of the CT antigen genes.
P-values <0.05 was considered significant for all analyses.
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